You are here: Industry Insights > CTX001

News List

Vertex, CRISPR Therapeutics’ blood disorder gene therapy shows more promise pharmatimes
June 16, 2021
New data presented at the European Hematology Association 2021 (EHA) virtual congress shows patients treated with Vertex/CRISPR Therapeutics’ blood disorder gene therapy CTX001 had ‘sustained response[s]’ to treatment’.
EMA PRIME status granted for Vertex, CRISPR Therapeutics’ gene therapy CTX001 pharmatimes
April 29, 2021
Vertex Pharmaceuticals and CRISPR Therapeutics’ gene therapy CTX001 has been granted a Priority Medicines (PRIME) designation from the European Medicines Agency (EMA).
Vertex, CRISPR Therapeutics’ sickle cell gene therapy wins PRIME designation pharmatimes
September 27, 2020
Vertex Pharmaceuticals and CRISPR Therapeutics have been awarded a Priority Medicines (PRIME) designation from the European Medicines Agency for their CRISPR/Cas9 gene therapy, designed to treat severe sickle cell disease (SCD).
CRISPR Therapeutics and Vertex Pharmaceuticals announce FDA RMAT designation granted to CTX001 to tr pharmaceutical-business-review
May 14, 2020
CRISPR Therapeutics and Vertex Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX001.